secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-031636
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q3 net loss $6.1M ($0.87/sh); PLACCINE NHP data shows similar protection to mRNA vaccine
--------------------------------------------------------------------------------

- Net loss of $6.1M ($0.87 per share) vs $5.4M ($0.94 per share) in Q3 2021; operating expenses rose 21% to $6.3M.
- Cash and investments of $43.4M; expects cash runway into 2025.
- Phase I/II OVATION 2 study with GEN-1 fully enrolled (110 patients); topline results expected H1 2024.
- PLACCINE NHP study: viral clearance >90% in vaccinated vs controls; protection comparable to commercial mRNA vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/0001493152-22-031636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer